Goldman Sachs has retained a Buy rating on Syngene International, setting a target price of ₹775, which implies a potential upside of 15.5% from the current market price of ₹670.75.
The brokerage highlighted that Syngene’s Q1 sales rose 11% year-on-year, surpassing Street expectations. The revenue growth was led by steady momentum across the company’s service platforms.
Goldman further noted that adjusted EBITDA margin improved to 23.6%, aided by a higher share of the contract research (CRO) business and operating leverage benefits. The company has indicated confidence in maintaining early-teens growth across verticals in FY26, reinforcing its consistent outlook.
Syngene’s focus on deepening partnerships and expanding its integrated research capabilities is expected to support medium-term growth.
Disclaimer: The views and recommendations expressed in this article are those of Goldman Sachs and do not represent the views of this publication. Investors are advised to consult their financial advisor before making any investment decisions.
